This work is dedicated to our friend and colleague, Professor WERNER SCHÄFER,
on the occasion of his 60th birthday (Z. Naturforsch. 27 b, 241-245 [1972] ; received December 31, 1971) Neuraminidase antibodies are known to inhibit hemagglutination by X-15 and X-15 (HK) recombinant viruses. However, the level of inhibition observed varies when different batches of chicken erythrocytes are employed, and the test generally detects neuraminidase antibodies with less sensitivity than an enzyme inhibition test. By titrating neuraminidase antibodies in the presence of anti-IgG globulins, with appropriate specificity, the hemagglutination-inhibition activity of neuraminidase antibodies is enhanced and the effect of cell variation is minimized. Consequently results obtained with this modified method for titrating neuraminidase antibodies become comparable to those obtained by measuring enzyme-inhibition. The improved hemagglutination-inhibition procedure possesses the important advantages of greater convenience and economy. Similar enhancing effects may also be obtained with egg white and guinea pig serum.
Neuraminidase (E.C. 3.2.1.18) is an enzymic component of influenza viruses, and shows antigenic specificity and variation independent of viral hemagglutinin 1 "" 4 
Materials and Methods

Human sera
For use in most experiments, pools were prepared employing equal aliquots from 24 or more serum pairs. These serum specimens were obtained from army recruits bled before and after vaccination in 1968 with 300 CCA units of A2/Aichi/2/68 virus. In one experiment paired specimens from this vaccine group and from another group receiving 250 CCA units of A2/ Japan/305/57 vaccine in 1957 were employed. The bleeding interval was two weeks in each case. Sera were used untreated in the neuraminidase enzyme inhibition (NI) test, and were treated with trypsin-periodate 10 for the hemagglutination inhibition (HI) test. All specimens were devoid of antibodies to the hemagglutinein of A/Equine/l/Prague/56 virus.
Viruses
Seeds of recombinant viruses X-15 and X-15(HK) were kindly supplied by Dr. E. D. KILBOURNE 
Biological materials used to enhance hemagglutinationinhibition
Chicken egg white was freshly prepared from 1 day eggs. Guinea pig serum, frozen at -65° in small lots, was thawed when required. For some tests complement was inactivated by heating the serum to 56° for 30 minutes. Fluorescein-conjugated anti-human IgG globulin (rabbit) was obtained from Sycco; (Lot 081169-C); Fluorescein-conjugated anti-human IgG globulin (goat) from Microbiological Associates (Lot 61226). All materials were diluted in phosphate buffered saline, pH 7.2.
Hemagglutination-inhibition (HI) tests
These tests were performed in perspex trays 10 . To determine the concentration of biological materials which could rightfully be employed in the HI test, each substance was first titrated to find the lowest dilution that did not show HI activity in a standard HI test using four virus agglutinating doses. Since such concentrations of biological materials might nevertheless bind some virus even though complete Hf was not observed, a further step w r as necessary. In this serial 0.2 ml dilutions of virus were prepared containing 4, 2, 1 and 0 agglutinating doses, to which were added either 0.2 ml of saline or dilutions of biological materials. These mixtures were then reacted with 0.4 ml of 0.5 percent chicken erythrocytes. In this way it was possible to establish the lowest dilution of each material that did not inhibit even one virus agglutinating dose. To measure HI by neuraminidase antibodies in the presence of biological enhancing materials the following procedure was adopted. 0.2 ml of virus antigen (4 agglutinating doses) was added to serial 2-fold dilutions of human serum and reacted at room temperature for 30 minutes. Then 0.2 ml of a solution of biological enhancing material was added, and reacted for 30 min. before adding 0.2 ml of a 1% chicken erythrocyte suspension. Hemagglutination patterns were read 1 hr. later, and the reciprocal of the highest dilution of human serum causing HI was taken as the serum titer. Enhancer dilutions referred to in results are initial dilutions, and were the highest at which maximum enhancing activity was obtained, consistent with a lack of non-specific HI.
Neuraminidase-inhibition (NI) tests
These tests were performed as previously described, using human serum Cohn fraction IV-4 as enzyme substrate 4 . Pre-immunization sera were generallv used to give final dilutions of l/20, 1/40, 1/80, and 1/160, and post-immunization sera 1/20, 1/80, 1/320, and 1/1280. Higher dilutions were used when necessary. Serum dilutions inhibiting 50% of control enzyme activity (measured in the absence of serum) w r ere obtained by graphical interpolation. and typical results are presented in Table 3 </<** </< </< </< 3 </< </< </< </< 4 </< </< </< </< 5 </< </< </< </< 6 </< </< </< </< 8 </< </< </< </< 9 </< </< </< </< 10 </< </< </< </< 11 </< </< </< </< 14 </< </< </< </< Overall, the results in Table 3 show that neuraminidase antibodies in human sera were consistently detected by HI using anti-human IgG globulin as enhancer, and the levels measured were in general of similar magnitude to those observed by NI.
Discussion
The X-15 hemagglutination-inhibition test for titrating neuraminidase antibodies has been regarded as insensitive 9 While the mechanism whereby neuraminidase antibodies inhibit viral hemagglutination is not known, it is suggested that the effect is due to steric hindrance of the viral surface by neuraminidase antibodies n . The effect of anti-human IgG globulin described here might be due to increased steric hindrance of the viral surface. Alternately it might be due to increased aggregation of virus particles by antibody.
The observation that guinea pig serum or highly diluted egg white has an enhancing effect in the HI test may be analogous to the use of serum cofactors in the HI test as described by STYK et al. [12] [13] [14] .
These substances probably all act by increasing the total number of macromolecules bound at the viral surface, so that together with antibodies, sufficient hindrance of the viral surface occurs to prevent heamagglutination 4 ' 14 . Binding of influenza-specific glycoprotein inhibitors to viral hemagglutinin might
